#esccongress2024

RHEIA Trial: women w/ severe AS, TAVI using SAPIEN 3/SAPIEN 3 Ultra superior to surgery for primary composite end point of death, stroke, or rehospitalization at one year: superiority driven by lower rate of rehospitalizations. #ESC2024 #ESCCongress2024 European Society of Cardiology
RTHahnMD17,149 просмотров • 1 год назад

Second T-TEER randomized trial: Tri-FR! Presented at #ESC2024 #ESCCongress2024 by Donal showing similar TRILUMINATE results: primary 1Yr endpoint driven by QoL but numerically lower mortality and HFH. Longer FU needed. European Society of Cardiology News European Society of Cardiology
RTHahnMD11,978 просмотров • 1 год назад
Больше нет контента для загрузки

